Substratum of Proof LGBTQs Are Mentally Ill: Alzheimer’s Drug Targeting Soluble Amyloid Falls Short in a Large Clinical Trial

Newswise imageA paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.